-
20 August 2025, Abbisko Therapeutics announced that the Center forDrug Evaluation (CDE) of the China National Medical Products Administration (NlPA) has cleared the lND application for Abbisko’sinvestigational oral PD-1 inhibitor, ABSK043, combined with Shanghai Alist Pharmaceuticals KRAS ...Read more »
-
Recently，Antengene’s Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate), an elderly patient with advanced gastric cancer who has progressed on multiple lines of chemotherapy, immunotherapy and targeted therapy despite extensive metastases achieved a complete response (CR) foll...Read more »
-
On August 13, 2025, Pacific Time, the official website of the 2025 World Conference on Lung Cancer (WCLC) released the selected research abstracts for this year’s conference, Among the highlights is the updated abstract for the first-in-human Phase 1 clinical trial of HLX43, Henlius’ PD-L1 ADC. A...Read more »
-
On August 7, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that PA3-17 injection has been proposed for inclusion in the breakthrough therapy designation, intended for the treatment of adult patients with relapsed/refractory T-cell acute lymp...Read more »
-
On August 11, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) indicated that InxMed’s application for IN10018 tabletshas been proposed for breakthrough therapy designation, intended for combination with D-1553 to treat locally advanced or metastatic KRA...Read more »
-
Mr. X is a patient in his 40s diagnosed with acral melanoma. After undergoing radical surgery following his diagnosis in 2015, his condition remained stable for nine years. Unfortunately, about a year ago, his disease recurred with metastases to both lungs. Despite receiving inguinal and pelvic l...Read more »
-
On July 31, AstraZeneca and Merck & Co. jointly announced that their PARP inhibitor Lynparza, in combination with Abiraterone and prednisolone, has been approved in China for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry germline or som...Read more »
-
On July 31, 2025，ImmuneOnco Biopharmaceuticals announce preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China. As of July 1, 2025,...Read more »
-
On July 30, the National Medical Products Administration (NMPA) officially approved the marketing of HICARA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who have received two or more lines of systemic therapy. This includes diffuse large B-cell ...Read more »
-
Recently, a patient with advanced pancreatic cancer who had failed multiple prior treatment lines achieved sustained tumor shrinkage after receiving KD-496 CAR-T cell therapy, with confirmed remission maintained at 180 days post-treatment. At present, there are still many clinical trials of new a...Read more »
-
On July 16, the top-tier international journal Nature Medicine published research data on SHR-A1904, an antibody-drug conjugate (ADC) targeting claudin 18.2 (CLDN18.2), for the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC). The researchers conducted a first-in...Read more »
-
July 17, 2025 – Innovent Biologics announced that Nature Medicine has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Publication in this leading international a...Read more »
Cooperative medical institution of
Beijing Cancer Hospital